Novo Nordisk’s Wegovy Pill Records Nearly 20,000 Prescriptions in First Week
TipRanks (Fri, 23-Jan 9:50 AM ET)
Novo Nordisk Wegovy pill had more than 18K prescriptions in first week
Seeking Alpha News (Fri, 23-Jan 9:30 AM ET)
Business Wire (Thu, 22-Jan 4:05 PM ET)
IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026
Business Wire (Tue, 20-Jan 4:45 PM ET)
Business Wire (Tue, 2-Dec 8:00 AM ET)
NEXT Oncology Expands to Japan in Joint Venture Partnership With Kansai Medical University
Business Wire (Wed, 5-Nov 9:00 AM ET)
IQVIA Reports Third-Quarter 2025 Results
Business Wire (Tue, 28-Oct 7:00 AM ET)
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Iqvia Hldgs trades on the NYSE stock market under the symbol IQV.
As of January 26, 2026, IQV stock price climbed to $238.06 with 313,327 million shares trading.
IQV has a beta of 0.96, meaning it tends to be less sensitive to market movements. IQV has a correlation of 0.18 to the broad based SPY ETF.
IQV has a market cap of $40.54 billion. This is considered a Large Cap stock.
Last quarter Iqvia Hldgs reported $4 billion in Revenue and $3.00 earnings per share. This beat revenue expectation by $26 million and exceeded earnings estimates by $.14.
In the last 3 years, IQV traded as high as $261.73 and as low as $134.65.
The top ETF exchange traded funds that IQV belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
IQV has outperformed the market in the last year with a return of +15.6%, while the SPY ETF gained +15.0%. In the last 3 month period, IQV beat the market returning +8.3%, while SPY returned +3.6%. However, in the most recent 2 weeks IQV has underperformed the stock market by returning -1.8%, while SPY returned -0.1%.
IQV support price is $231.18 and resistance is $239.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IQV shares will trade within this expected range on the day.
